UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS

被引:10
作者
Atun, Rifat A. [1 ]
Gurol-Urganci, Ipek [1 ]
Sheridan, Desmond [2 ,3 ,4 ,5 ]
机构
[1] Imperial Coll London, Ctr Hlth Management, Tanaka Business Sch, South Kensington Campus, London SW7 2AZ, England
[2] Imperial Coll London, Dept Natl Heart, London W2 1PG, England
[3] Imperial Coll London, Lung Inst, London W2 1PG, England
[4] St Marys Hosp, Dept Natl Heart, London W2 1PG, England
[5] St Marys Hosp, Lung Inst, London W2 1PG, England
关键词
Diffusion of innovation; pharmaceuticals; regulatory environment;
D O I
10.1142/S1363919607001709
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
Multiple interacting factors influence the uptake and diffusion of medicines which are critical to improving health. However, there is a gap in our knowledge on how regulatory policies and other national health systems attributes combine to impact on the utilisation of innovative drugs, and health system goals and objectives. Our review demonstrates that strong regulation adversely affects access to innovation, reduces incentives for research-based firms to develop innovative products and leads to short-and long-term welfare losses. Short-term efficiency gains from reducing pharmaceutical expenditures may actually increase total healthcare costs, reduce user choice, and in some cases, adversely affect health outcomes. Decision makers need to adopt a holistic approach to policy making, and consider potential impact of regulations on the uptake and diffusion of innovations, innovation systems and health system goals.
引用
收藏
页码:299 / 321
页数:23
相关论文
共 137 条
[91]  
Pavcnik N, 2000, NBER WORKING PAPERS
[92]  
Pilote L, 2002, CAN MED ASSOC J, V167, P246
[93]   Incentives and pharmaceutical reimbursement reforms in Spain [J].
Puig-Junoy, J .
HEALTH POLICY, 2004, 67 (02) :149-165
[94]   What is required to evaluate the impact of pharmaceutical reference pricing? [J].
Puig-Junoy J. .
Applied Health Economics and Health Policy, 2005, 4 (2) :87-98
[95]   How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study [J].
Rafferty, T ;
WilsonDavis, K ;
McGavock, H .
BRITISH MEDICAL JOURNAL, 1997, 315 (7101) :166-170
[96]  
Rocchi Francesca, 2004, J Ambul Care Manage, V27, P127
[97]  
Rogers E.M, 2005, DIFFUSION INNOVATION
[98]   EXAMINING PRODUCT RISK IN CONTEXT - MARKET WITHDRAWAL OF ZOMEPIRAC AS A CASE-STUDY [J].
ROSSDEGNAN, D ;
SOUMERAI, SB ;
FORTESS, EE ;
GURWITZ, JH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (16) :1937-1942
[99]   Diffusion of innovations: treatment of Alzheimer's disease in Germany [J].
Ruof, J ;
Mittendorf, T ;
Pirk, O ;
von der Schulenburg, JMG .
HEALTH POLICY, 2002, 60 (01) :59-66
[100]   CHARGING FOR HEALTH-CARE - EVIDENCE ON THE UTILIZATION OF NHS PRESCRIBED DRUGS [J].
RYAN, M ;
BIRCH, S .
SOCIAL SCIENCE & MEDICINE, 1991, 33 (06) :681-687